Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Radiothérapie corporelle stéréotaxique (SBRT) pour le traitement précoce du carcinome adénoïde kystique oligométastatique : l'essai SOLAR

30 septembre 2026 mis à jour par: Jonathan Schoenfeld, MD, MPH, Dana-Farber Cancer Institute

The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival.

The name(s) of the study intervention involved in this study is:

  • Stereotactic Body Radiation Therapy (SBRT)

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This is a randomized phase II, open-label and non-blinded two-arm study aimed to investigate the potential benefit of treating oligometastatic adenoid cystic carcinoma (ACC) with early initiation of stereotactic body radiotherapy (SBRT). Given the overall uncertainty about the role of local therapy in the treatment of ACC, there is also a prospective observational cohort that will investigate outcomes following local ablative treatments in patients with advanced or metastatic ACC.

This research study is investigating how the specialized and focused stereotactic body radiation therapy (SBRT) impacts disease progression, quality of life, and overall survival in patients with a limited number of metastases (one to five) from their adenoid cystic carcinoma cancer. The use of SBRT to treat all areas of disease after early spread of ACC is investigational. SBRT is a more focused form of radiation compared to the palliative radiation typically received per standard of care treatment. Recent retrospective studies conducted suggest that patients with adenoid cystic carcinoma cancer may benefit from early initiation of a targeted radiation therapy.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. After enrollment participants will be randomized into two groups: Standard of Care or Stereotactic body radiotherapy (SBRT). All participants in the study, regardless of treatment regimen, will be followed for up to 10 years.

It is expected that about 32 people will take part in this research study.

Two organizations, Gateway for Cancer Research and the Adenoid Cystic Carcinoma Research Foundation (ACCRF), are supporting this research study by providing funding.

Type d'étude

Interventionnel

Inscription (Estimé)

32

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

  • États-Unis
    • California
      • San Francisco, California, États-Unis, 94158
        • Recrutement
        • University of California, San Francisco
        • Contact:
        • Chercheur principal:
          • Sue Yom, MD, PhD
    • Illinois
      • Chicago, Illinois, États-Unis, 60637
        • Recrutement
        • University of Chicago
        • Chercheur principal:
          • Alexander T Pearson, MD, PhD
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Recrutement
        • Brigham and Women's Hospital
        • Chercheur principal:
          • Jonathan D Schoenfeld, MD, MPH
        • Contact:
      • Boston, Massachusetts, États-Unis, 02215
        • Recrutement
        • Dana Farber Cancer Institute
        • Contact:
        • Chercheur principal:
          • Jonathan D Schoenfeld, MD, MPH
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • MD Anderson Cancer Center
        • Contact:
        • Chercheur principal:
          • Matthew S Ning, MD, MPH

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Subject must have histologically confirmed adenoid cystic carcinoma (ACC) of any primary site with distant metastases detected clinically or on imaging (biopsy of metastatic disease preferred, but not required)

  • Cohort 1

    • One to five detectable sites of metastatic disease at any organ or site (including bone and CNS involvement)

      • Maximum size of 3 cm for brain lesions.
      • Note: Measurable disease is not required
      • Note: Patients with isolated intracranial disease for whom SRS would be the preferred standard of care are not eligible.
      • Note: Patients may have additional sites of disease for which radiation is not feasible or indicated provided this disease is: 1) Less than 1 cm in maximum diameter on most recent imaging; or 2) Stable over the last 3 months as determined by the investigator

  • Cohort 2

    • At least 1 site of non-osseous disease

  • Cohort 1

    • All (up to 5) metastatic foci should be amenable to SBRT as per review by a radiation oncologist based on protocol specified dose / dose constraints (there is no prespecified minimum or maximum size)

  • Cohort 2

    • At least one metastatic focus amenable to local ablative treatment with any of the following: radiation therapy; radiofrequency, microwave, or cryoablation; bland or chemoembolization

  • Cohort 1

    • Primary tumor either controlled, or amenable for local treatment with SBRT
    • Defined as no evidence of progression at primary or local site of disease (if known) within 6 months prior to enrollment

  • Age 18 years or older

  • ECOG performance status of 0-2

  • Prior systemic therapy is allowed but no therapy (cytotoxic or molecularly targeted agents) 2 weeks prior to the first fraction of radiotherapy, and until after the last fraction of SBRT.

  • Cohort 1

    • For patients with metastases that have been previously treated (prior resection, radiotherapy, radiofrequency or cryoablation):

      • If the previously treated site is controlled based on imaging, the patient is eligible for this trial and does not need further treatment of the controlled site
      • If the previously treated site is not controlled based on imaging, the patient is eligible for this trial as long as the site is amenable to SBRT

  • Ability to understand and the willingness to sign a written informed consent document.

  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of (chemo)radiation therapy.

"Women of childbearing potential (WOCBP)" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.

  • Men who are sexually active with WOCBP must agree to use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 1 month after treatment. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception. See Appendix B for further guidance on contraception.

Exclusion Criteria:

  • Cohort 1

    • Subject who has received systemic therapy for treatment of ACC within 2 weeks of enrollment.

  • Evidence of need for urgent surgical intervention for metastatic CNS or spine disease.

  • Cohort 1

    • Alternative locally ablative therapies received (radiofrequency ablation, cryotherapy, or [chemo]embolization) for any metastatic foci planned for SBRT at the time of study enrollment that precludes administration of SBRT.

  • Bone metastasis in a femoral bone for which surgical stabilization is recommended.

  • Cohort 1

    • Active disease >1 cm that is progressing and not amenable to SBRT.

  • Pregnant or lactating women.

  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions: include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer, and low-risk prostate adenocarcinoma being managed with active surveillance. A history of another separate malignancy in remission without evidence of active disease in the last 2 years is permitted.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Standard of Care (Cohort 1)

Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
Autre: Standard of Care

Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
Expérimental: Stereotactic Body Radiotherapy (SBRT) 1-5 Metastatic Sites (Cohort 1)

Participants will be randomly assigned and receive SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer.

After SBRT is completed participant may go on to receive systemic therapy (like chemotherapy, immunotherapy, or targeted therapies) per discretion of their treating physician.
Radiation: SBRT

SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer

Autres noms:
  • Radiothérapie corporelle stéréotaxique
Aucune intervention: Local Ablative Therapy (Cohort 2)

Participants embarking on standard of care local ablative therapy (not limited to radiofrequency, microwave, or cryoablation, bland or chemoembolization, palliative radiotherapy, or surgical metastasectomy) not eligible for cohort 1 will be enrolled and followed.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression Free Survival (PFS) (Cohort 1)
Délai: Time from randomization to local, regional, distant progression or death due to any cause, whichever occurs first, assessed up to 5 years

Assessed using RECIST v1.1 and Kaplan-Meier
Time from randomization to local, regional, distant progression or death due to any cause, whichever occurs first, assessed up to 5 years
Local Control Rate (Cohort 2)
Délai: 2 years from enrollment

Estimating 2-year local control rate following local treatment of ACC lesions. Assessed using RECIST v1.1.
2 years from enrollment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Survival (OS)
Délai: Time from randomization to death from any cause or date last known alive, assessed up to 5 years

Assessed using RECIST v1.1 and Kaplan-Meier
Time from randomization to death from any cause or date last known alive, assessed up to 5 years
Toxicity Rate
Délai: Enrollment to end of treatment up to 2 years

Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Enrollment to end of treatment up to 2 years
Quality of Life (QOL) assessments by FACT-G
Délai: Baseline and every 3 months for 2 years

Descriptive statistics will be performed to characterize QOL data
Baseline and every 3 months for 2 years
Local Disease Control Rate
Délai: Time from randomization to free of locoregional progression, assessed up to 5 years

Free of locoregional progression within irradiated oligometastatic sites, assessed using Kaplan-Meier
Time from randomization to free of locoregional progression, assessed up to 5 years
Time to next systemic therapy for progression of disease
Délai: Time from randomization to initiation of systemic therapy for progression of disease, assessed up to 5 years

Assessed using Kaplan-Meier
Time from randomization to initiation of systemic therapy for progression of disease, assessed up to 5 years
Time to local therapy for progression of disease
Délai: Time from randomization to initiation of local therapy for progression of disease, assessed up to 5 years

Assessed using Kaplan-Meier
Time from randomization to initiation of local therapy for progression of disease, assessed up to 5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dana-Farber Cancer Institute

Collaborateurs

Adenoid Cystic Carcinoma Research Foundation
Gateway for Cancer Research

Les enquêteurs

  • Chercheur principal: Jonathan D Schoenfeld, MD, MPH, Brigham and Women's Hospital

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 décembre 2021

Achèvement primaire (Estimé)

1 juin 2028

Achèvement de l'étude (Estimé)

1 juin 2030

Dates d'inscription aux études

Première soumission

3 mai 2021

Première soumission répondant aux critères de contrôle qualité

7 mai 2021

Première publication (Réel)

12 mai 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 21-171

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner